Single-fraction ultrahigh dose-rate proton therapy showed early safety in thoracic metastases
Single-fraction proton treatment produced pain responses without grade 2 or higher related toxicity in 10 patients with thoracic bone metastases.
Single-fraction proton treatment produced pain responses without grade 2 or higher related toxicity in 10 patients with thoracic bone metastases.
Four-dimensional prompt-gamma imaging detected clinically relevant proton range shifts associated with anatomical change during pancreatic proton therapy.
Circulating lymphocyte counts remained stable during brain radiotherapy without concurrent chemotherapy, consistent with low estimated blood and cervical lymph-node dose
Skin-constrained intensity-modulated proton therapy produced acute dermatitis rates comparable with photon postmastectomy radiotherapy (grade ≥2: 47% vs 48%).
Pencil-beam proton reirradiation for locoregional breast cancer recurrence achieved 95% three-year overall survival, with severe toxicity uncommon despite a 21% rib-fracture rate.